PRODUCT DATA SHEET



Bioworld Technology, Inc.

Recombinant Human Endothelial-Monocyte A Activating Polypeptide II (rHuEMAP-II)

Catalog Number: PR1015 Source: Escherichia coli. Quantity:5µg/20µg/1.0mg

Description

EMAP-II is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.

Molecular Weight:

Approximately 18.3 KDa, a single non-glycosylated polypeptide chain containing 166 amino acids.

Purity:

>98% by SDS-PAGE and HPLC analyses.

Biological Activity:

Determined by the apoptotic effect on MCF-7 cells using a concentration of 20-40 ng/ml, corresponding to a Specific Activity of $\Box 2.5 \times 104 \text{ IU/mg}$.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

Lyophilized from a 0.2mm filtered concentrated solution in 20mM PB, pH 7.4, 130mM NaCl.

AA Sequence:

SKPIDVSRLDLRIGCIITARKHPDADSL YVEEVDVGEIAPRTVVSGLVNHVPLEQ

Bioworld Technology, Inc.

1660 South Highway 100, Suite 500 St. Louis Park, MN

M Q N R M V I L L C N L K P A K M R G V L S Q A M V M C A S S P E K I E I L A P P N G S V P G D R I T F D A F P G E P D K E L N P K K K I W E Q I Q P D L H T N D ECVATYKGVPFEVKGKGVCRAQTMSN SGIK

Endotoxin:

Less than 1EU/mg of rHuEMAP-II as determined by LAL method.

Reconstitution:

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20°C. Further dilutions should be made in appropriate buffered solutions

Storage:

This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.

This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. Made in China

MADE IN CHINA

Email: info@biogot.com Tel: 0086-025-86371664 Fax:0086-025-86213570